GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » EBITDA Margin %

IMRN (Immuron) EBITDA Margin % : -190.83% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Immuron EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Immuron's EBITDA for the six months ended in Jun. 2024 was $-3.23 Mil. Immuron's Revenue for the six months ended in Jun. 2024 was $1.69 Mil. Therefore, Immuron's EBITDA margin for the quarter that ended in Jun. 2024 was -190.83%.


Immuron EBITDA Margin % Historical Data

The historical data trend for Immuron's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron EBITDA Margin % Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.64 -5,683.93 -366.36 -206.61 -140.36

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -194.40 -338.07 -147.74 -87.82 -190.83

Competitive Comparison of Immuron's EBITDA Margin %

For the Biotechnology subindustry, Immuron's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Immuron's EBITDA Margin % falls into.



Immuron EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Immuron's EBITDA Margin % for the fiscal year that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-4.57/3.256
=-140.36 %

Immuron's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-3.227/1.691
=-190.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuron  (NAS:IMRN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Immuron EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Immuron's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron Business Description

Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.